Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs
AssigneeGenentech, Inc.
InventorMark Sliwkowski
Life of this patent
Estimating the term…
Abstract
The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and EGFR-targeted drugs.
Claims20
A method of treating cancer in a human, wherein the cancer expresses epidermal growth factor receptor (EGFR) and ErbB2, comprising administering to the human therapeutically effective amounts of an ErbB2 antibody which blocks by 50% or greater binding of monoclonal antibody 2C4 (ATCC HB-12697) to ErbB2, and an EGFR-targeted drug.
A method of treating cancer in a human, wherein the cancer expresses epidermal growth factor receptor (EGFR) and ErbB2, comprising administering to the human therapeutically effective amounts of an ErbB2 antibody which blocks formation of an ErbB hetero-oligomer, and an EGFR-targeted drug.
A method of treating cancer in a human comprising administering to the human therapeutically effective amounts of rhuMAb 2C4, and an EGFR-targeted drug selected from the group consisting of chimerized 225 (C225), ZD1839, and CP-358774, wherein the cancer is selected from the group consisting of non small cell lung cancer (NSCLC), pancreatic cancer, colon cancer, rectal cancer, colorectal cancer, head and neck cancer, and ovarian cancer.
Dependencies are inferred from the claim text.